From May 5-9, RDD 2024 will welcome an international gathering of OINDP experts to the JW Marriott … [Read More...] about RDD 2024 to cover the latest OINDP development trends
RDD 2024 to cover the latest OINDP development trends
The DDL New Researcher Network Expands its Activities
By Julia Berends, Cord Kühnl, and Lucy Goodacre The New Researcher Network (NRN) was founded as … [Read More...] about The DDL New Researcher Network Expands its Activities
Q&A with Copley’s Clair Brooks on in vitro testing for LGWP MDI reformulation
Copley Application Specialist Clair Brooks discusses new EMA guidance on data requirements … [Read More...] about Q&A with Copley’s Clair Brooks on in vitro testing for LGWP MDI reformulation
Latest news
FTC tells court hearing Teva’s patent infringement case against Amneal that Teva patents listed for ProAir HFA should be de-listed
The US Federal Trade Commission (FTC) recently filed an amicus brief in a patent infringement case filed by Teva against Amneal after Amneal submitted an ANDA for a generic version of Teva's ProAir HFA albuterol MDI in July 2023. In the brief, the FTC contends that the court should grant Amneal's … [Read More...] about FTC tells court hearing Teva’s patent infringement case against Amneal that Teva patents listed for ProAir HFA should be de-listed
Marinomed announces deals for Carragelose nasal sprays in Hungary and in Gulf countries
Marinomed Biotech has announced a new agreement with VitaPlus for distribution of one of Marionomed's Carragelose nasal sprays in Hungary and another agreement with GAIA Healthcare for marketing of two Carragelose nasal sprays in the Gulf region. According to the announcement, VitaPlus could launch … [Read More...] about Marinomed announces deals for Carragelose nasal sprays in Hungary and in Gulf countries
Intravacc announces data from Phase 1 study of Avacc 10 intranasal SARS-CoV-2 vaccine as a booster
Intravacc has announced that a Phase 1 study of Avacc 10 intranasal vaccine as a booster against SARS-CoV-2 induced a mucosal response in subjects who received the higher of two doses tested, and the vaccine was well tolerated. The company announced in November 2022 that it was initiating the Phase … [Read More...] about Intravacc announces data from Phase 1 study of Avacc 10 intranasal SARS-CoV-2 vaccine as a booster
Tonix gets Rare Pediatric Disease Designation for TNX-2900 intranasal potentiated oxytocin for PWS
According to Tonix Pharmaceuticals, the FDA has granted Rare Pediatric Disease Designation to TNX-2900 intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS) in children and adolescents. Tonix licensed TNX-2900 from the French National Institute of Health and Medical … [Read More...] about Tonix gets Rare Pediatric Disease Designation for TNX-2900 intranasal potentiated oxytocin for PWS
Blue Lake announces preliminary data from Phase 1/2a trial of BLB201 intranasal RSV vaccine in young children
Blue Lake Biotechnology has announced initial results from a Phase 1/2a clinical trial of its BLB201 intranasal vaccine against severe respiratory syncytial virus disease in children aged 8 months to 59 months with or without prior RSV infection. The company has previously announced results from a … [Read More...] about Blue Lake announces preliminary data from Phase 1/2a trial of BLB201 intranasal RSV vaccine in young children
Other recent news
- Inhalon reports data from Phase 1b trial of IN-006 inhaled regdanvimab
- TFF says it will prioritize development of its tacrolimus DPI
- RDD 2024 to cover the latest OINDP development trends
- AstraZeneca follows Boehringer Ingelheim in capping inhaler costs for some US patients
- Kindeva appoints Jenifer Riter as VP of Analytical Services